Drug Classes: Comprehensive Classification of Therapeutic Drug Categories and Mechanisms

Exhaustive guide to drug classification including nervous system, cardiovascular, respiratory, GI, endocrine, antimicrobial, anticancer, immunomodulatory, and musculoskeletal drug classes with mechanisms, indications, and key representatives.

Medications & Pharmacology 5 min read
This content is for informational purposes only. Always consult a healthcare professional.

Introduction

Drug classification organizes medications by therapeutic use, mechanism of action, or chemical structure. Understanding drug classes facilitates therapeutic decision-making, predicts adverse effects, identifies drug interactions, and guides appropriate prescribing. This guide covers major drug classes across therapeutic categories.

Nervous System Drugs

Central Nervous System Depressants

Class Mechanism Examples Primary Indications Key Adverse Effects
Benzodiazepines Positive allosteric modulation of GABA-A Diazepam, lorazepam, alprazolam, clonazepam Anxiety, seizures, insomnia, muscle spasm, alcohol withdrawal Sedation, tolerance, dependence, amnesia, respiratory depression
Barbiturates Direct GABA-A activation, Cl- channel opening Phenobarbital, pentobarbital, thiopental Seizures (phenobarbital), anesthesia (thiopental) Respiratory depression, dependence, narrow TI, CYP induction
Z-drugs Selective GABA-A alpha-1 subunit modulation Zolpidem, zopiclone, eszopiclone Insomnia Similar to benzodiazepines, limited to sleep
Antihistamines (sedating) H1 receptor antagonism Diphenhydramine, hydroxyzine, doxylamine Insomnia, allergies, motion sickness Anticholinergic effects, next-day sedation

Antidepressants

Class Mechanism Examples Onset Adverse Effects
SSRIs Selective serotonin reuptake inhibition Fluoxetine, sertraline, citalopram, escitalopram, paroxetine 2-6 weeks GI upset, sexual dysfunction, insomnia, serotonin syndrome risk
SNRIs Serotonin and norepinephrine reuptake inhibition Venlafaxine, duloxetine, desvenlafaxine 2-6 weeks Similar to SSRIs, plus hypertension (venlafaxine), withdrawal syndrome
TCAs Serotonin/norepinephrine reuptake inhibition + other receptors Amitriptyline, nortriptyline, imipramine, desipramine 2-4 weeks Anticholinergic, antihistaminergic, cardiac arrhythmia risk, overdose lethal
MAOIs MAO-A and/or MAO-B inhibition Phenelzine, tranylcypromine, selegiline 2-4 weeks Hypertensive crisis with tyramine (diet restrictions), drug interactions
Atypicals Various mechanisms (e.g., dopamine, melatonin) Bupropion (NDRI), mirtazapine (alpha-2 antagonist), trazodone 2-4 weeks Varies: bupropion (seizure risk), mirtazapine (sedation, weight gain)

Antipsychotics

Generation Mechanism Examples EPS Risk Metabolic Risk Other Key Effects
First-generation (Typical) D2 receptor antagonism Haloperidol, chlorpromazine, fluphenazine High (especially high-potency) Low Prolactin elevation, tardive dyskinesia, NMS
Second-generation (Atypical) D2 + 5-HT2A antagonism Risperidone, olanzapine, quetiapine, aripiprazole, clozapine Low-moderate (except risperidone) High (olanzapine, clozapine) Weight gain, diabetes, dyslipidemia; clozapine: agranulocytosis

Opioid Analgesics

Class Examples Potency (vs. morphine) Indications Key Adverse Effects
Natural opioids Morphine, codeine 1, 0.1 Moderate-severe pain Respiratory depression, constipation, tolerance, dependence, addiction
Semisynthetic Oxycodone, hydrocodone, hydromorphone 1.5, 1, 5 Same Same profile; oxycodone high abuse liability
Synthetic Fentanyl, methadone, tramadol, meperidine 100, 8-12, 0.1, 0.1 Fentanyl: severe acute/chronic pain; Methadone: addiction maintenance Same; fentanyl: ultra short-acting; methadone: QT prolongation
Partial agonists Buprenorphine 25-40 Opioid addiction, moderate pain Ceiling effect on respiratory depression; withdrawal precipitation

Cardiovascular Drugs

Antihypertensives

Class Mechanism Examples Key Benefits Key Adverse Effects
ACE inhibitors Inhibit angiotensin-converting enzyme Lisinopril, enalapril, ramipril Renal protection in diabetes, heart failure Cough (10-20%), hyperkalemia, angioedema
ARBs Block angiotensin AT1 receptor Losartan, valsartan, candesartan Same as ACEi, better tolerated Lower cough incidence, otherwise similar
CCBs (dihydropyridine) L-type calcium channel blockade (vascular) Amlodipine, nifedipine Isolated systolic HTN, angina Peripheral edema, headache, flushing
CCBs (non-dihydropyridine) L-type calcium channel blockade (cardiac) Diltiazem, verapamil Rate control in AF, angina Bradycardia, constipation (verapamil), heart block
Thiazide diuretics Na-Cl cotransporter inhibition in DCT HCTZ, chlorthalidone First-line HTN, CHF Hypokalemia, hyponatremia, hyperuricemia, hyperglycemia
Beta-blockers Beta-1 (and beta-2) antagonism Metoprolol, atenolol, carvedilol CAD, HF, post-MI, migraine Fatigue, bradycardia, bronchospasm (non-selective)
Alpha-1 blockers Alpha-1 antagonism Doxazosin, terazosin, tamsulosin BPH, HTN (not first-line) Orthostatic hypotension, dizziness

Antiarrhythmics (Vaughan Williams Classification)

Class Mechanism Examples Indications Proarrhythmia Risk
I Sodium channel blockade
IA Moderate Na blockade + K blockade Quinidine, procainamide AF, VT TdP (quinidine)
IB Mild Na blockade Lidocaine, mexiletine VT (post-MI) Low
IC Strong Na blockade Flecainide, propafenone AF, PSVT High (CAST trial)
II Beta-blockade Metoprolol, atenolol Rate control, post-MI Low
III Potassium channel blockade Amiodarone, sotalol, ibutilide, dofetilide AF, VT TdP (except amiodarone)
IV Non-DHP CCB Verapamil, diltiazem Rate control, PSVT Bradycardia, heart block

Endocrine Drugs

Class Mechanism Examples Indications Key Adverse Effects
Biguanides AMPK activation, hepatic glucose reduction Metformin T2DM first-line GI intolerance, lactic acidosis (rare)
Sulfonylureas K-ATP channel closure, insulin secretion Glipizide, glyburide, glimepiride T2DM Hypoglycemia, weight gain
DPP-4 inhibitors Inhibit GLP-1 degradation Sitagliptin, saxagliptin, linagliptin T2DM Well-tolerated, pancreatitis risk (rare)
GLP-1 receptor agonists GLP-1 receptor activation Liraglutide, semaglutide, tirzepatide T2DM, obesity GI upset, pancreatitis, thyroid C-cell tumors
SGLT2 inhibitors Renal glucose reabsorption inhibition Empagliflozin, dapagliflozin, canagliflozin T2DM, HF, CKD UTIs, DKA (euglycemic), Fournier’s gangrene
Insulin Exogenous insulin replacement Lispro, glargine, detemir, degludec T1DM, advanced T2DM Hypoglycemia, weight gain, injection site reactions

Antimicrobials

Class Mechanism Examples Spectrum Key Adverse Effects
Penicillins Cell wall synthesis inhibition (transpeptidase) Amoxicillin, piperacillin-tazobactam Broad Allergy (1-10%), diarrhea, C. difficile
Cephalosporins Cell wall synthesis inhibition Cephalexin (1st), cefuroxime (2nd), ceftriaxone (3rd) Broad (generation-dependent) Allergy (cross-reactivity ~5-10%), C. difficile
Carbapenems Cell wall synthesis inhibition Meropenem, ertapenem Very broad (including ESBL) Seizures (imipenem), C. difficile
Macrolides 50S ribosomal inhibition Azithromycin, clarithromycin, erythromycin Respiratory, atypical pathogens GI upset, QT prolongation (erythromycin, clarithromycin)
Fluoroquinolones DNA gyrase/topoisomerase IV inhibition Ciprofloxacin, levofloxacin, moxifloxacin Broad (gram-negative, atypicals) Tendon rupture, QT prolongation, C. difficile
Aminoglycosides 30S ribosomal inhibition Gentamicin, tobramycin, amikacin Gram-negative Nephrotoxicity, ototoxicity, neuromuscular blockade
Tetracyclines 30S ribosomal inhibition Doxycycline, minocycline, tigecycline Broad (atypicals, acne, malaria) Photosensitivity, teeth discoloration, esophageal ulceration
Vancomycin Cell wall synthesis inhibition (D-ala-D-ala) Vancomycin Gram-positive (MRSA) Red man syndrome, nephrotoxicity, thrombophlebitis

Cancer Drugs

Class Mechanism Examples Indications Key Adverse Effects
Alkylating agents DNA crosslinking Cyclophosphamide, cisplatin, carboplatin Various solid tumors, lymphomas Myelosuppression, nausea, nephrotoxicity, hemorrhagic cystitis
Antimetabolites Nucleic acid synthesis inhibition Methotrexate, 5-FU, gemcitabine, cytarabine Various Myelosuppression, mucositis, hepatotoxicity
Topoisomerase inhibitors Topoisomerase I/II poisoning Irinotecan, etoposide, doxorubicin Various Myelosuppression, cardiotoxicity (doxorubicin), delayed diarrhea (irinotecan)
Tyrosine kinase inhibitors RTK inhibition Imatinib, erlotinib, sorafenib, osimertinib Specific mutations Hypertension, rash, diarrhea, hepatotoxicity
Monoclonal antibodies Specific antigen targeting Rituximab (CD20), trastuzumab (HER2) Hematologic, solid tumors Infusion reactions, immunosuppression, cardiotoxicity (trastuzumab)
Immune checkpoint inhibitors PD-1/PD-L1, CTLA-4 blockade Pembrolizumab, nivolumab, ipilimumab Multiple cancers Immune-related adverse events (colitis, pneumonitis, dermatitis, endocrinopathies)

Conclusion

Drug classification by therapeutic class and mechanism of action enables systematic understanding of pharmacology. Each class shares common mechanisms, indications, adverse effects, and drug interactions. This framework supports rational drug selection, combination therapy decisions, and effective management of adverse effects and drug interactions in clinical practice.